|
Post by sportsrancho on Apr 25, 2018 17:12:39 GMT -5
|
|
|
Post by afrezzamiracle on Jun 29, 2018 0:03:01 GMT -5
|
|
|
Post by mnkdfann on Jun 29, 2018 0:30:20 GMT -5
"H.C. Wainwright analyst Oren Livnat is out today with a bullish research note on shares of MannKind (NASDAQ:MNKD), after the distressed insulin maker presented additional data for Afrezza from the STAT study at the American Diabetes Association’s (ADA) 78th Scientific Sessions." I wish his track record was better: www.tipranks.com/analysts/oren-livnat?ref=track"Ranked #4,452 out of 4,825 Analysts on TipRanks (#10,429 out of 11,334 overall experts)"
|
|
|
Post by goyocafe on Jun 29, 2018 0:39:01 GMT -5
"H.C. Wainwright analyst Oren Livnat is out today with a bullish research note on shares of MannKind (NASDAQ:MNKD), after the distressed insulin maker presented additional data for Afrezza from the STAT study at the American Diabetes Association’s (ADA) 78th Scientific Sessions." I wish his track record was better: www.tipranks.com/analysts/oren-livnat?ref=track"Ranked #4,452 out of 4,825 Analysts on TipRanks (#10,429 out of 11,334 overall experts)" Very bold statements from an analyst, regardless of track record. ADA, repeat after Oren: ”We believe this was an eye-opening experience for many that Afrezza’s defining differentiation isn’t that it’s inhalable, rather that it really is the best meal-time insulin, full stop. Afrezza is the only truly ultra-rapid-acting insulin that most closely mimics healthy endogenous insulin action, and we don’t see anything else in development yet that comes close. We find it remarkable that ADA hype is dominated by progress in continuous glucose monitoring (CGM), pumps, and software algorithms, and the combination of thereof in the quest for the “artificial” pancreas holy grail. Yet, those approaches, with their billions in sales, still deliver boluses of older, slower insulin analogs for meal-time glucose control.”
|
|
|
Post by traderdennis on Jun 29, 2018 14:13:12 GMT -5
"H.C. Wainwright analyst Oren Livnat is out today with a bullish research note on shares of MannKind (NASDAQ:MNKD), after the distressed insulin maker presented additional data for Afrezza from the STAT study at the American Diabetes Association’s (ADA) 78th Scientific Sessions." I wish his track record was better: www.tipranks.com/analysts/oren-livnat?ref=track"Ranked #4,452 out of 4,825 Analysts on TipRanks (#10,429 out of 11,334 overall experts)" Very bold statements from an analyst, regardless of track record. ADA, repeat after Oren: ”We believe this was an eye-opening experience for many that Afrezza’s defining differentiation isn’t that it’s inhalable, rather that it really is the best meal-time insulin, full stop. Afrezza is the only truly ultra-rapid-acting insulin that most closely mimics healthy endogenous insulin action, and we don’t see anything else in development yet that comes close. We find it remarkable that ADA hype is dominated by progress in continuous glucose monitoring (CGM), pumps, and software algorithms, and the combination of thereof in the quest for the “artificial” pancreas holy grail. Yet, those approaches, with their billions in sales, still deliver boluses of older, slower insulin analogs for meal-time glucose control.” Sounds like Wainwright is getting a piece of the pipe finding pie.
|
|
|
Post by goyocafe on Jun 29, 2018 14:22:27 GMT -5
Very bold statements from an analyst, regardless of track record. ADA, repeat after Oren: ”We believe this was an eye-opening experience for many that Afrezza’s defining differentiation isn’t that it’s inhalable, rather that it really is the best meal-time insulin, full stop. Afrezza is the only truly ultra-rapid-acting insulin that most closely mimics healthy endogenous insulin action, and we don’t see anything else in development yet that comes close. We find it remarkable that ADA hype is dominated by progress in continuous glucose monitoring (CGM), pumps, and software algorithms, and the combination of thereof in the quest for the “artificial” pancreas holy grail. Yet, those approaches, with their billions in sales, still deliver boluses of older, slower insulin analogs for meal-time glucose control.” Sounds like Wainwright is getting a piece of the pipe finding pie. Yep. Doesn’t look like anyone is falling for it this time.
|
|
|
Post by goyocafe on Jul 1, 2018 12:32:29 GMT -5
Will be interesting if we pick up any analyst coverage this year. I would assume we wouldn't get any new ones unless it were a buy rating. Wonder if anyone is following MNKD unofficially waiting for something to fall into place to give them confidence to say "buy". Will Q1 financials make guidance look probable or out of reach... or something in between. Just random musings. No new ones, but we lost Maxim on June 15. What a fickle bunch. They only started coverage on August 17, 2017. I wonder if MNKD takes long enough to update the website to remove them form their list, if they’ll be back in, calling MNKD their top pick for 2018/2019? investors.mannkindcorp.com/stock-information/analyst-coverage?mobile=1
|
|
|
Post by sportsrancho on Jul 1, 2018 14:38:49 GMT -5
I believe they’re history along with their buddy, Aegis Capital Corp. that was in the Matt time frame.
|
|
|
Post by mnkdfann on Jul 1, 2018 18:08:18 GMT -5
Will be interesting if we pick up any analyst coverage this year. I would assume we wouldn't get any new ones unless it were a buy rating. Wonder if anyone is following MNKD unofficially waiting for something to fall into place to give them confidence to say "buy". Will Q1 financials make guidance look probable or out of reach... or something in between. Just random musings. No new ones, but we lost Maxim on June 15. What a fickle bunch. Where was that announced? A few people said Maxim dropped coverage, but I've yet to see proof.
|
|
|
Post by goyocafe on Jul 1, 2018 18:54:26 GMT -5
|
|
|
Post by sportsrancho on Jul 1, 2018 19:13:02 GMT -5
No new ones, but we lost Maxim on June 15. What a fickle bunch. Where was that announced? A few people said Maxim dropped coverage, but I've yet to see proof. expertgazette.com/2018/06/25/analysts-review-under-consideration-mannkind-corporation-mnkd-3/Maxim Group “Terminates” Mannkind Corporation (NASDAQ:MNKD) in a research note issued to investors on 6/15/18 to Sell with price target of $0. Additionally on 3/01/18 Maxim Group “Downgrades” Mannkind Corporation (NASDAQ:MNKD) to Sell and on 11/01/17 Maxim Group “Downgrades” the stock to Hold. Furthermore on 10/10/17 H.C. Wainwright “Initiates Coverage On” the stock to Buy at $7.
|
|
|
Post by mnkdfann on Jul 1, 2018 19:54:53 GMT -5
Thanks to you both for the links. Ouch!
|
|
|
Post by Clement on Jul 3, 2018 10:42:24 GMT -5
new on Fidelity this morning: Institutional Shareholder Services resumes coverage for MNKD with overweight recommendation.
|
|
|
Post by rockstarrick on Jul 3, 2018 11:10:14 GMT -5
new on Fidelity this morning: Institutional Shareholder Services resumes coverage for MNKD with overweight recommendation. 1) Overweight as part of a three-tiered rating system, along with "underweight" and "equal weight", is used by financial analysts to indicate a particular stock's attractiveness. If a stock is recommended to be "overweight", the analyst opines that the stock is better value for money than others.[2] 2) An investment portfolio judged to be overweight indicates that an investor holds proportionately more than the benchmark weight of a certain asset (a share, bond, industry/sector, country, currency, or asset class, etc.).[3]
|
|
|
Post by centralcoastinvestor on Jul 3, 2018 11:18:31 GMT -5
new on Fidelity this morning: Institutional Shareholder Services resumes coverage for MNKD with overweight recommendation. Well finally some good news on the analysts front. As they say “That is better than a poke in the eye with a sharp stick.” (I grew up in a small town so you have to forgive the sayings.)
|
|